Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant

por Tsuruda, Masafumi, Yoshino, Hirofumi, Okamura, Shunsuke, Kuroshima, Kazuki, Osako, Yoichi, Sakaguchi, Takashi, Sugita, Satoshi, Tatarano, Shuichi, Nakagawa, Masayuki, Enokida, Hideki
Publicado 2020

Potential new therapy of Rapalink‐1, a new generation mammalian target of rapamycin inhibitor, against sunitinib‐resistant renal cell carcinoma

por Kuroshima, Kazuki, Yoshino, Hirofumi, Okamura, Shunsuke, Tsuruda, Masafumi, Osako, Yoichi, Sakaguchi, Takashi, Sugita, Satoshi, Tatarano, Shuichi, Nakagawa, Masayuki, Enokida, Hideki
Publicado 2020

Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma

por Yoshino, Hirofumi, Yamada, Yasutoshi, Enokida, Hideki, Osako, Yoichi, Tsuruda, Masafumi, Kuroshima, Kazuki, Sakaguchi, Takashi, Sugita, Satoshi, Tatarano, Shuichi, Nakagawa, Masayuki
Publicado 2020

Characterization of PHGDH expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation

por Yoshino, Hirofumi, Enokida, Hideki, Osako, Yoichi, Nohata, Nijiro, Yonemori, Masaya, Sugita, Satoshi, Kuroshima, Kazuki, Tsuruda, Masafumi, Tatarano, Shuichi, Nakagawa, Masayuki
Publicado 2020

EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer

por Okamura, Shunsuke, Yoshino, Hirofumi, Kuroshima, Kazuki, Tsuruda, Masafumi, Osako, Yoichi, Sakaguchi, Takashi, Yonemori, Masaya, Yamada, Yasutoshi, Tatarano, Shuichi, Nakagawa, Masayuki, Enokida, Hideki
Publicado 2021